Ligen G. Liu
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax.
Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax.
Journal: Frontiers in oncology
Published: March 11, 2026
Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
Journal: Annals of hematology
Published: February 11, 2026
Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
Journal: Annals of hematology
Published: August 21, 2025
Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol.
Journal: Future oncology (London, England)
Published: February 26, 2025
Noscapine derivative 428 suppresses ferroptosis through targeting GPX4.
Journal: Redox biology
Published: February 01, 2025
Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP.
Journal: Annals of hematology
Published: December 08, 2024
Nonionotropic action of an acid-sensing ion channel inhibits leukemogenesis in the acidic bone marrow niche.
Journal: The Journal of clinical investigation
Published: November 11, 2024
Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
Journal: Bone marrow transplantation
Published: October 12, 2024
Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.
Journal: Annals of hematology
Published: October 10, 2024
BCAT1 contributes to the development of TKI-resistant CML.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: October 03, 2024
Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia.
Journal: Chinese medical journal
Published: September 25, 2024
Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.
Journal: American journal of hematology
Published: July 10, 2024
Last Updated: 09/26/2026